FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1815 December 14, 2000 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: Schömig et al. (Aug. 10 issue)¹ report the results of a randomized clinical trial in which coronary stenting combined with platelet glycoprotein IIb/IIIa blockade (abciximab) was compared with fibrinolysis with a tissue plasminogen activator (alteplase) for the treatment of acute myocardial infarction. The authors show that myocardial salvage and clinical outcome (the incidence of recurrent infarction and survival) were significantly better in the group of patients who underwent stenting and received abciximab than in those who received alteplase.

Although not specifically stated, the main objective of the study was to assess the efficacy of each method of . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.